RT Journal Article
SR Electronic
T1 Hemochromatosis mutations, dementia and brain iron deposition: a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.18.20134536
DO 10.1101/2020.06.18.20134536
A1 David Melzer
A1 Janice L Atkins
A1 Luke C Pilling
A1 Christine J Heales
A1 Sharon Savage
A1 Chia-Ling Kuo
A1 George A Kuchel
A1 David C Steffens
YR 2020
UL http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134536.abstract
AB Importance Brain iron deposition is common in dementia, but its causal significance is uncertain. The HFE p.C282Y homozygous mutation in European ancestry populations can lead to iron overload and hemochromatosis, mainly in males. Data on brain outcomes in homozygotes are scarce.Objective To estimate HFE variant associations with MRI features plus incident dementia diagnoses during follow-up in a large community based cohort.Design UK Biobank cohort with follow-up in routine hospitalization records (mean 8.8 years). MRI imaging available on a participant subset scanned 2014 to 2018.Setting Community cohort participants across England, Wales and Scotland.Participants European ancestry participants (n=451,186) aged 40 to 70 years at baseline, including 2,890 p.C282Y homozygotes (predominantly without baseline haemochromatosis diagnoses). MRI scanning on 9,464 males and 10,475 females, including 40 male and 75 female p.C282Y homozygotes.Exposure HFE C282Y and H63D genetic variantsMain outcome and measures Brain MRI site specific T2* measures (lower values associated with iron deposition) and gray matter volumes. Incident dementia diagnoses during follow-up.Results Male p.C282Y homozygotes had lower T2* measures in several brain areas including the thalamus (beta = -1.04 standard deviations, 95% CI -1.33 to -0.76, multiple testing adjusted p-value=4.9*10-10), putamen and hippocampus, compared to those without HFE mutations. Male homozygotes also had smaller gray matter volumes in the putamen (beta -0.80 sd, 95%CI -1.12 to - 0.47, adjusted p=2.2*10-4) and ventral striatum.Diagnoses of incident dementia (Hazard Ratio HR=2.27; 95% CI 1.36 to 3.80, p=0.002) were more common in p.C282Y homozygous men, as were delirium diagnoses (HR=2.04, CI 1.09 to 3.82, p=0.03), but there was no association with Stroke.In p.C282Y homozygote females and p.C282Y/H63D heterozygotes, MRI associations were less marked.Conclusion and Relevance In a community sample, men with the HFE p.C282Y homozygote genotype had more brain iron deposition, smaller specific gray matter volumes, and increased incidence of dementia. As iron overload in hemochromatosis is treatable, early intervention may prevent or limit related brain pathology in male HFE p.C282Y homozygotes.Question Is the hemochromatosis HFE p.C282Y homozygous variant in men associated with brain MRI features and incident dementia?Findings On MRI, p.C282Y homozygote males had evidence of more iron deposition in areas including the thalamus, putamen and hippocampus, plus smaller putamen gray matter volumes, compared to men without HFE mutations. In 451,186 UK Biobank participants during the mean 8.8 year follow-up, incident dementia diagnoses were more than twice as common in the 1,294 homozygous men.Meaning As iron overload in hemochromatosis is treatable, early intervention may prevent or limit related brain pathology in male HFE p.C282Y homozygotes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by UK Medical Research Council award MR/S009892/1 (PI Melzer), which supports JLA. DM and LCP are supported by the University of Exeter Medical School, and in part by the University of Connecticut School of Medicine. SS is supported by the College of Life and Environmental Sciences, University of Exeter. Input from CLK, GAK and DCS was supported by the University of Connecticut. The authors acknowledge the use of the University of Exeter High-Performance Computing (HPC) facility in carrying out this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank ethical approval was from the North West Multi-Centre Research Ethics Committee. The current analysis was approved under UK Biobank application 14631 (PI David Melzer).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesStudy data is available directly from UK Biobank following an application.